
TORONTO, Oct. 18 /CNW/ - Patheon Inc. (TSX: PTI) announced today that its subsidiary, CEPH International Corporation, received a reply from the U.S. Food and Drug Administration (FDA) to its response letter filed on October 6, 2005 in response to the FDA Warning Letter dated September 13, 2005. In its reply, the FDA stated it had found that the commitments to the corrective actions outlined in CEPH's response letter will address the FDA's concerns raised in the Warning Letter. CEPH is currently implementing the corrective action program. During the next few days, CEPH will commence manufacturing qualification and validation batches of the Omnicef oral powder for suspension product in accordance with the corrective action program. CEPH anticipates that by early November it will complete qualification and validation testing of these batches of product and, subject to satisfactory test results, will release these batches of product to the client. The FDA has indicated that it wants to be notified when production of the product has been re-initiated. CEPH currently expects that during the month of November it will be in a position to notify the FDA that production has been re-initiated and that it will be prepared for an FDA re-inspection to verify the implementation of the corrective actions. Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. With the addition of its wholly owned subsidiary MOVA Pharmaceutical Corporation, acquired in December 2004, Patheon operates a network of 14 facilities in the United States, Canada and Europe, employing more than 5,900 people and serving a client base of 180 pharmaceutical and biotechnology companies. This news release contains forward-looking statements with respect to Patheon, including its business operations and strategy and financial performance and condition. Although management believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from expectations include, but are not limited to, currency fluctuations, the level of outsourcing services required by the pharmaceutical companies (and in particular our clients), the impact of changes in pharmaceutical development and manufacturing regulations and general economic and market factors (including inflation and changes in laws) and other factors discussed in materials filed with applicable securities regulatory authorities from time to time. %SEDAR: 00001700E